<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>In patients with structural <z:e sem="disease" ids="C0018799" disease_type="Disease or Syndrome" abbrv="">heart disease</z:e>, <z:hpo ids='HP_0004756'>ventricular tachycardia</z:hpo> (VT) worsens the clinical condition and may severely affect the short- and long-term prognosis </plain></SENT>
<SENT sid="1" pm="."><plain>Several therapeutic options can be considered for the management of this <z:hpo ids='HP_0011675'>arrhythmia</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>Among others, catheter ablation, a closed-chest therapy, can prevent <z:hpo ids='HP_0011675'>arrhythmia</z:hpo> recurrences by abolishing the arrhythmogenic substrate </plain></SENT>
<SENT sid="3" pm="."><plain>Over the last two decades, different techniques have been developed for an effective approach to both tolerated and untolerated VTs </plain></SENT>
<SENT sid="4" pm="."><plain>The clinical outcome of patients undergoing ablation has been evaluated in multiple studies </plain></SENT>
<SENT sid="5" pm="."><plain>This editorial gives an overview of the role, methodology, clinical outcome and innovative approaches in catheter ablation of VT </plain></SENT>
</text></document>